The FDA approved Sanofi’s Infilbray (venglustat) on November 18, 2026, introducing the first approved treatment for the neurological manifestations of Type 3 Gaucher disease. The once-daily oral medicine is indicated for adults and children weighing at least 15 kilograms. (Reuters’ coverage of the Infilbray approval)
The approval addresses a longstanding gap in care. Enzyme replacement therapy can manage systemic manifestations of Gaucher disease, but its neurological complications have remained beyond the reach of available treatments.
| Item | Details |
|---|---|
| Company | Sanofi; approval granted to its Genzyme subsidiary |
| Medicine | Infilbray (venglustat) |
| Modality | Small-molecule glucosylceramide synthase inhibitor |
| Approved indication | Neurological manifestations of Type 3 Gaucher disease |
| Eligible patients | Adults and pediatric patients weighing at least 15 kg |
| Administration | Oral, once daily |
| Supporting trial | Phase 3 LEAP2MONO (NCT05222906) |
Gaucher disease is an inherited disorder caused by deficient activity of glucocerebrosidase, an enzyme involved in breaking down certain fatty substances. Their accumulation can cause problems such as an enlarged liver and spleen, anemia and bone disease. Type 3 also affects the central nervous system, causing difficulties with balance, coordination, speech and cognition.
Infilbray inhibits glucosylceramide synthase, reducing production of substances that accumulate in the disease. Its ability to cross the blood-brain barrier allows it to act within the brain—an important distinction when treating neurological manifestations.
What the Infilbray Phase 3 Trial Demonstrated
The randomized, double-blind LEAP2MONO trial enrolled 43 patients aged 12 years and older whose systemic disease had already been stabilized with enzyme replacement therapy. Participants received either daily oral Infilbray or intravenous imiglucerase every two weeks for 52 weeks.
The primary analysis combined changes in motor coordination and cognitive function, assessed using a modified four-item Scale for the Assessment and Rating of Ataxia and the Repeatable Battery for the Assessment of Neuropsychological Status. Infilbray demonstrated statistically significant superiority over imiglucerase on this combined neurological assessment, with p=0.0137. (Sanofi’s approval announcement and LEAP2MONO results)
The finding applies to the combined analysis; it does not establish that every individual symptom improved. The 52-week result also does not establish a cure or determine how long the neurological benefit will persist.
The trial’s minimum enrollment age of 12 years should be distinguished from the approved indication, which covers adults and pediatric patients weighing at least 15 kilograms.
Safety remains part of the treatment decision. Reported adverse effects include gastrointestinal symptoms and mood-related effects. The FDA also highlighted serious psychiatric risks, including suicidal ideation and behavior, alongside potential lens changes in younger patients and fetal-development risks identified in animal studies. (FDA’s Infilbray approval announcement)
I particularly welcome approvals that bring a treatment option to patients whose needs have long remained unmet. Although existing therapies can manage the systemic manifestations of Type 3 Gaucher disease, its neurological symptoms have lacked an approved treatment. Addressing that gap represents meaningful progress for patients and families who have continued to face these difficulties despite ongoing care. I hope more companies continue investing in rare diseases with limited treatment options.
For another recent treatment approval, read my previous article on Nelkarmi’s FDA accelerated approval for ALK-positive lung cancer.


Leave a Reply